<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01437826</url>
  </required_header>
  <id_info>
    <org_study_id>IST-1988</org_study_id>
    <nct_id>NCT01437826</nct_id>
  </id_info>
  <brief_title>Antioxidant Supplement and Reduction of Metachronous Adenomas of the Large Bowel: a Double Blind Randomized Trial</brief_title>
  <official_title>Evaluation of the Efficacy of a Combination of Micronutrients (Vitamin A, C, E, Selenium and Zinc) in Reducing the Incidence of Colorectal Metachronous Adenomas. A Double Blind, Phase III, Randomized, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LILT (Italian league against cancer)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial was aimed at evaluating the efficacy of a multiagent antioxidant compound (vitamin
      A, C, E, selenium and zinc) in reducing the incidence of metachronous adenomas of the large
      bowel after endoscopic polypectomy. This is a randomized study: a 50% reduction in the
      incidence of metachronous adenomas was expected in patients allocated to the &quot;active&quot;
      compound (intervention) arm as compared to those assigned to a placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adenomatous polyps (or adenoma) are benign lesions of the large bowel that are frequent in
      people aged 60 or more: about one in four of them has at least one adenoma. In time, adenoma
      could progress to cancer. Even though only a small rate of adenomas will develop into cancer
      almost 70-80% of colorectal cancer origin from an adenoma and colorectal cancer is one of the
      most frequent malignant tumors in the western world. Several epidemiological studies showed
      that subjects who had low intake and/or low blood levels of selenium were at increased risk
      of developing colorectal cancer.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    50% of eligible patients refused to enter the study
  </why_stopped>
  <start_date>March 1988</start_date>
  <completion_date type="Actual">June 1996</completion_date>
  <primary_completion_date type="Actual">June 1996</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>occurrence of metachronous adenomas or cancer detected during endoscopic follow up examinations</measure>
    <time_frame>five years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">411</enrollment>
  <condition>Colorectal Adenomas</condition>
  <arm_group>
    <arm_group_label>antioxidants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tablets composed of 200 mcg selenium [as l-selenomethionine], 30 mg zinc, 2 mg vitamin A [retinol], 180 mg vitamin C [ascorbic acid] and 30 mg vitamin E [D-α-tocopherol acetate]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo had an identical appearance as intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antioxidants</intervention_name>
    <description>tablets composed of 200 mcg selenium [as l-selenomethionine], 30 mg zinc, 2 mg vitamin A [retinol], 180 mg vitamin C [ascorbic acid] and 30 mg vitamin E [D-α-tocopherol acetate]</description>
    <arm_group_label>antioxidants</arm_group_label>
    <other_name>Bio-selenium, Pharma Nord (DK)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo had an identical appearance as intervention</description>
    <arm_group_label>Sugar pill</arm_group_label>
    <other_name>placebo was provided by Pharma Nord</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 25-75 years

          -  at least one histologically confirmed adenoma endoscopically removed from the large
             bowel resulting in a polyp-free colon-rectum (clean colon).

        Exclusion Criteria:

          -  polypectomy performed more than 6 months before enrolment in the trial

          -  history of Familial Adenomatous Polyposis

          -  inflammatory bowel disease

          -  adenoma with invasive carcinoma

          -  ten or more adenomas

          -  large sessile adenoma (3 cm or more

          -  colorectal resection

          -  invasive cancer at any site

          -  life-threatening and/or chronic heart, liver or kidney diseases

          -  current use of vitamin or calcium supplements

          -  mental disability
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luigina A Bonelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Azienda Ospedale Università San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genova - Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRCCS Azienda Ospedale Università San Martino - IST Istituto Nazionale per la Ricerca sul Cancro</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2011</study_first_submitted>
  <study_first_submitted_qc>September 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2011</study_first_posted>
  <last_update_submitted>September 19, 2011</last_update_submitted>
  <last_update_submitted_qc>September 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</investigator_affiliation>
    <investigator_full_name>Luigina Bonelli</investigator_full_name>
    <investigator_title>MD, responsible of the unit of secondary prevention and screening</investigator_title>
  </responsible_party>
  <keyword>chemoprevention</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>metachronous adenoma</keyword>
  <keyword>randomized trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin A</mesh_term>
    <mesh_term>Antioxidants</mesh_term>
    <mesh_term>Retinol palmitate</mesh_term>
    <mesh_term>Selenium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

